Synergistic activity of meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii.

IF 1.5 4区医学 Q2 Medicine

the Indian Journal of Pharmacy Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI:10.4103/ijp.ijp_635_24

I Amruthavarshini, Deepashree Rajshekar, Raghavendra Rao, Akshat Mysore Harish

{"title":"Synergistic activity of meropenem and sulbactam against carbapenem-resistant Acinetobacter baumannii.","authors":"I Amruthavarshini, Deepashree Rajshekar, Raghavendra Rao, Akshat Mysore Harish","doi":"10.4103/ijp.ijp_635_24","DOIUrl":null,"url":null,"abstract":"Objective: The purpose of this study was to determine the in vitro synergistic effect of meropenem and sulbactam drug combinations through checkerboard assay against Carbapenem-resistant Acinetobacter baumannii (CRAB) to establish potential treatment options.Materials and methods: CRAB was cultured from the clinical samples of Endotracheal aspirate, blood, pus, throat swab, and urine specimens from 80 patients with suspected nosocomial infection in 1 year. Minimum inhibitory concentration (MIC) was determined for meropenem and sulbactam drugs individually. Synergism was determined for meropenem + sulbactam combinations using checkerboard assay.Results: All the 80 CRAB isolates were found to be resistant (>16 MIC) for Meropenem drug and 64 out of 80 showed resistant (>16 MIC) to sulbactam, 14 isolates displayed intermediate (8 MIC), and 2 of them were found to be sensitive (<2 MIC). The checkerboard assay showed 66.25% of synergism between meropenem and sulbactam followed by 25% of additivity and 8.75% of them were found to be indifferent.Conclusion: In the current checkerboard assay, we observed potential synergistic activity between meropenem and sulbactam against CRAB isolates which indicates that this combination can be an appealing strategy in the treatment of nosocomial infections caused by CRAB isolates.","PeriodicalId":49189,"journal":{"name":"the Indian Journal of Pharmacy","volume":"57 5","pages":"322-328"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"the Indian Journal of Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijp.ijp_635_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The purpose of this study was to determine the in vitro synergistic effect of meropenem and sulbactam drug combinations through checkerboard assay against Carbapenem-resistant Acinetobacter baumannii (CRAB) to establish potential treatment options.

Materials and methods: CRAB was cultured from the clinical samples of Endotracheal aspirate, blood, pus, throat swab, and urine specimens from 80 patients with suspected nosocomial infection in 1 year. Minimum inhibitory concentration (MIC) was determined for meropenem and sulbactam drugs individually. Synergism was determined for meropenem + sulbactam combinations using checkerboard assay.

Results: All the 80 CRAB isolates were found to be resistant (>16 MIC) for Meropenem drug and 64 out of 80 showed resistant (>16 MIC) to sulbactam, 14 isolates displayed intermediate (8 MIC), and 2 of them were found to be sensitive (<2 MIC). The checkerboard assay showed 66.25% of synergism between meropenem and sulbactam followed by 25% of additivity and 8.75% of them were found to be indifferent.

Conclusion: In the current checkerboard assay, we observed potential synergistic activity between meropenem and sulbactam against CRAB isolates which indicates that this combination can be an appealing strategy in the treatment of nosocomial infections caused by CRAB isolates.

Abstract Image

查看原文本刊更多论文

美罗培南和舒巴坦对耐碳青霉烯鲍曼不动杆菌的协同作用。

目的：通过棋盘法测定美罗培南与舒巴坦联合用药对耐碳青霉烯鲍曼不动杆菌（CRAB）的体外增效作用，确定潜在的治疗方案。材料与方法：从80例1年内怀疑医院感染的患者的气管内吸入物、血液、脓、咽拭子、尿液等临床标本中培养CRAB。分别测定了美罗培南和舒巴坦的最低抑菌浓度（MIC）。采用棋盘法测定美罗培南+舒巴坦联合用药的增效作用。结果：80株CRAB对美罗培南均耐药（>16 MIC）， 64株对舒巴坦耐药（>16 MIC）， 14株为中间耐药（8 MIC）， 2株敏感(结论：在目前的棋盘试验中，我们观察到美罗培南和舒巴坦对螃蟹分离株的潜在协同作用，这表明这种组合可能是治疗螃蟹分离株引起的医院感染的一种有吸引力的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

the Indian Journal of Pharmacy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.60

自引率

4.20%

发文量

期刊介绍： Indian Journal of Pharmacology accepts, in English, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor, case reports and interesting fillers. Articles concerning all aspects of pharmacology will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome.